Introduction {#s1}
============

Intellectual disability (ID) is characterized by significantly impaired intellectual and adaptive function, and is often defined by an IQ score below 70 in addition to deficits in two or more adaptive behaviors (e.g., social skills, problem solving) that affect everyday life. ID is also subdivided into syndromal ID, where ID is associated with other clinical, morphological, or behavioral symptoms or non-syndromal ID, where intellectual deficits appear without other associated defects (Stevenson et al., [@B33]). X-linked intellectual disability (XLID) refers to forms of ID typically associated with X-linked recessive inheritance. Mutations in monogenic XLID have been reported in \>100 genes, many of which are now used in routine diagnostic screening panels (Basehore et al., [@B2]). Despite screening for mutations in selected known XLID genes by conventional linkage/candidate gene analysis or array CGH for examining copy number variants (CNVs), large number of families mapping to the X-chromosome remained unresolved (Lubs et al., [@B15]). These cases either represent undiscovered disease-relevant mutations in known genes, or causal mutations in novel XLID loci that remain to be identified.

Mutation and gene discovery in XLID has recently been transformed by large-scale DNA sequencing approaches coupled with stringent variant filtering (Tarpey et al., [@B35]; Rauch et al., [@B25]; Gilissen et al., [@B5]; Redin et al., [@B27]; Hu et al., [@B7]; Niranjan et al., [@B19]; Tzschach et al., [@B36]). For example, a recent study in a large cohort of unresolved families with XLID revealed that 20% of families carried pathogenic variants in established XLID genes (Hu et al., [@B7]), as well as revealing seven novel XLID genes (*CLCN4, CNKSR2, FRMPD4, KLHL15, LAS1L, RLIM*, and *USP27X*) and two candidates (*CDK16* and *TAF1*). Another strategy, known as Affected Kindred/Cross-Cohort Analysis (Niranjan et al., [@B19]) has also identified variants in known and novel XLID genes including *PLXNA3, GRIPAP1, EphrinB1* and *OGT*. However, analysis of next-generation data sets has also highlighted a number of XLID genes where truncating variants or previously published "mutations" are observed at a relatively high frequency in normal controls, calling into question whether certain single nucleotide variants (SNVs) are indeed causal (Tarpey et al., [@B35]; Piton et al., [@B23]). This highlights the need for integrating structure-function based approaches into the analysis pipeline for validating potentially disease-causing variants.

In this study, we have combined next-generation sequencing, variant filtering and structure-function assays to resolve the cause of XLID in a large family (K8010) with NS-XLID, with variable macrocephaly and macro-orchidism (Johnson et al., [@B9]). The previous clinical study in this family revealed ten affected males and two affected females in two generations, as well as four obligatory carriers. Most affected males exhibited macrocephaly and macro-orchidism, which are typical signs of the fragile X syndrome. However, cytogenetic testing and analysis of *FMR1* indicated they did not have this syndrome. It was also notable that some normal males in the family also exhibited macro-orchidism and macrocephaly. Linkage analysis suggested that the causative gene was located on Xp11-q21 (Johnson et al., [@B9]). We present compelling evidence that the likely cause of XLID in this family is a missense mutation in *ARHGEF9*, encoding a neuronal RhoGEF known as collybistin (CB) involved in both inhibitory synaptic organization and mammalian target of rapamycin complex 1 (mTORC1) signaling pathways (Machado et al., [@B16]).

Materials and Methods {#s2}
=====================

Subjects {#s2-1}
--------

Family K8010 was previously reported by Johnson et al. ([@B9]). Briefly, the males resembled those with fragile X syndrome in that they had macrocephaly (abnormally large head, typically 2.5 standard deviations above normal for weight and gender), macro-orchidism (abnormally large testes), blue eyes, prominent jaw and long facies. Additionally, one carrier female was described as being "slow". However, using linkage analysis, the locus was mapped to Xq12-q21 rather than Xq27.3. Additionally, *FMR1* gene analysis was negative (Johnson et al., [@B9]).

Exon Capture and DNA Sequencing {#s2-2}
-------------------------------

Next generation sequencing was conducted as a partial follow-up of 15 probands from a large scale sequencing of 718 X-chromosome genes in 208 XLID probands (Tarpey et al., [@B35]). The deep sequencing was conducted using the Agilent SureSelect Human X chromosome kit (Takano et al., [@B34]). A novel and unique mutation in *ARHGEF9*, c.1012C\>T, was noted in K8010. Segregation analysis was conducted using Sanger sequencing.

Polymorphism Analysis {#s2-3}
---------------------

Screening of 566 normal individuals (420 males, 146 females) for the *ARHGEF9* c.1012C\>T variant was carried out using allele-specific amplification. Primers used were: *ARHGEF9*-ASOF 5′-TACGGCCGCAACCAGCtGt 3′ and *ARHGEF9*-ASOR 5′-CCCATCAGTATTTGCCCACT-3′. The ASOF primer recognized the mutation, which is indicated by the "t" at the 3′ end of the primer. The third base from the 3′ end was also changed from an "a" to a "t" to increase the specificity of the PCR. The ASOR primer was designed so that the T~m~ of both primers were similar and to generate a PCR product of above 500 bp. Gradient duplex PCR analysis was conducted using mutation and normal samples to choose the optimum annealing temperature. High-throughput duplex PCR analysis with a mutation and normal sample as positive and negative controls.

Molecular Modeling of the Collybistin R338W Mutation {#s2-4}
----------------------------------------------------

The non-synonymous R338W substitution was modeled into the structure of rat CB (PDB 2DFK; Xiang et al., [@B37]) using the swapaa command in Chimera (Pettersen et al., [@B22]) using the Dunbrack backbone-dependent rotamer library (Dunbrack, [@B3]). This took into account the lowest clash score, highest number of H-bonds and highest rotamer probability. Electrostatic potential of wild-type and R338W mutant CB was calculated using the Adaptive Poisson-Boltzmann Solver (APBS) web server (Baker et al., [@B1]; <http://www.poissonboltzmann.org/>).

Site-Directed Mutagenesis and Expression Constructs {#s2-5}
---------------------------------------------------

Full-length human CB cDNAs were cloned into the vector pRK5 as previously described (Kalscheuer et al., [@B11]). Mutations were introduced into pRK5myc-hCB3~SH3−~ construct using the QuikChange site-directed mutagenesis kit (Agilent) and confirmed by Sanger DNA sequencing of the entire coding region.

PI~3~P Pull-Down Assays {#s2-6}
-----------------------

Human embryonic kidney (HEK293) cells were grown in DMEM supplemented with 10% (v/v) fetal bovine serum at 37°C, 5% CO~2~ and transfected with 4 μg pRK5myc-hCB3~SH3−~ wild-type or R338W mutants using FuGENE (Roche). After 24 h, transfected cells were solubilized in a buffer containing Triton X-100 (Sigma-Aldrich), 1%; 150 mM NaCl; 50 mM Tris, pH 7.4, with protease inhibitor cocktail (Roche, Sussex, UK). Insoluble material was removed by centrifugation at 16, 100× g for 20 min. Phosphatidylinositol-3-phosphate (PI~3~P/PtdIns-3-P) agarose beads (40 μl; Eschelon Biosciences) were incubated with cell lysates for 2 h at 4°C. Beads were washed four times in buffer. Proteins were eluted from beads by heating at 98°C for 3 min in 2 × sample loading buffer and then subjected to SDS-PAGE. Proteins binding to beads were detected by Western blotting using mouse anti-c-myc antibody (Sigma, 1:1000) and HRP-conjugated goat anti-mouse (Santa Cruz, 1:2000). Immunoreactivity was visualized using West Pico Chemiluminescent Substrate (Pierce). Expression levels of hCB3~SH3−~ and hCB3~SH3−~R338W, and PI~3~P pulldown assay results were assessed using an unpaired, two-tailed Student's *t*-test.

Gephyrin Clustering Assays {#s2-7}
--------------------------

These were performed essentially as previously described (Harvey et al., [@B6]). HEK293 cells were co-transfected with pRK5myc-hCB3~SH3−~ wild-type, pRK5myc-hCB3~SH3+~ wild-type, pRK5myc-hCB3~SH3−~ R338W, pRK5myc-hCB3~SH3−~ R290H or pRK5myc-hCB3~SH3−~ R356N/R357N constructs at a 1:1 ratio with pEGFP-gephyrin using electroporation (Gene Pulser II, Bio-Rad). Cells were fixed after 24 h for 2 min in 4% (w/v) PFA in PBS. Immunostaining to detect CB was performed using a mouse anti-c-myc antibody (1:200, Sigma) and detected using an AlexaFluor 546 goat anti-mouse secondary antibody (1:600; Invitrogen). Counterstaining for cell nuclei was performed with DAPI (1:500; Life Technologies). Confocal microscopy was performed using a Zeiss LSM 710 META. All images were taken with a × 63 objective.

Results {#s3}
=======

Identification of a R338W Mutation in *ARHGEF9* in Family K8010 {#s3-1}
---------------------------------------------------------------

X-chromosome exome sequencing of an individual male in family K8010 followed by bioinformatics analysis and filtering against publicly-available datasets revealed a novel missense change in *ARHGEF9*, chrX:62,885,810G\>A, c.1012C\>T; p.R338W, predicted as probably damaging (PolyPhen-2, score 1.000), damaging (SIFT) and a Combined Annotation Dependent Depletion (CADD) score of 19.37 (possibly pathogenic). This suggested that this missense mutation could be responsible for XLID, macrocephaly and macro-orchidism in this family. Subsequent segregation analysis using Sanger DNA sequencing indicated that the *ARHGEF9* c.1012C\>T variant co-segregated with the phenotype in all individuals tested (Figures [1A,B](#F1){ref-type="fig"}).

![**Identification of a R338W mutation in *ARHGEF9* in family K8010. (A)** Pedigree of the K8010 family, which has been updated. Open symbols represent normal individuals, filled squares represent affected males. Individuals tested for the nucleotide substitution in each family are indicated with either a T (mutant allele) or a C (normal allele). **(B)** DNA sequence electropherograms for the c.1012C\>T mutation reported in this study. **(C)** Schematic of the human collybistin (CB) protein with a regulatory SH3 domain, a catalytic RhoGEF domain and a pleckstrin homology (PH) domain. The relative locations of known missense and nonsense mutations in *ARHGEF9* are shown. **(D)** Sequence alignments of CB proteins from various species showing the high conservation of R338W in the PH domain. Note that R338W is not one of the known PI~3~P binding residues (R356 and R357, green).](fnmol-08-00083-g0001){#F1}

Collybistin Mutation R338W is Predicted to Disrupt PH Domain Folding {#s3-2}
--------------------------------------------------------------------

CB belongs to the Dbl family of guanine nucleotide exchange factors, occurs in multiple splice variants (Kins et al., [@B12]; Harvey et al., [@B6]) and is specific for Cdc42, a small GTPase belonging to the Rho family (Xiang et al., [@B37]). CB has a multi-domain structure consisting of a regulatory SH3 domain, a catalytic RhoGEF domain and a pleckstrin homology (PH) domain (Figure [1C](#F1){ref-type="fig"}). Residue R338W is the first reported *ARHGEF9* missense mutation affecting a highly conserved residue in the PH domain (Figure [1D](#F1){ref-type="fig"}). Previous nonsense and missense mutations in CB have affected residues in the N-terminus (p.Q2X; Shimojima et al., [@B29]), regulatory SH3 domain (p.G55A; Harvey et al., [@B6]) and catalytic RhoGEF domain (p.R290H; Lemke et al., [@B13]; Papadopoulos et al., [@B21]). To assess how the R338W substitution might disrupt CB function, molecular modeling was performed using the structure of rat CB (PDB 2DFK; Xiang et al., [@B37]), which has a sequence identity of 85.5% to human CB \[aligned using HHalign algorithm (Söding, [@B31]) within Clustal-Omega (Sievers et al., [@B30])\]. The R338W change replaces a long, electropositive side-chain (arginine) with a large non-charged, hydrophobic side-chain (tryptophan). Positively-charged residues are thought to be critical for interaction of the PH domain with the membrane (Xiang et al., [@B37]) and R338W clearly changes the electrostatic potential of the PH domain, as visualized using APBS (Figures [2A--C](#F2){ref-type="fig"}). R338W is also predicted to introduce a number of clashes with surrounding residues (e.g., N335, K363; Figures [2D,E](#F2){ref-type="fig"}), which is also predicted to affect interactions with membrane and the fold of the PH domain.

![**The R338W substitution is predicted to influence the electrostatic potential and folding of the CB PH domain. (A)** Arginine 338 is located on the surface of the CB structure within the pleckstrin homology (PH) domain (circled by a black dotted line). It resides within a cleft between turns of β-sheet secondary structure **(D)**, in close proximity to other electropositive side-chains. Therefore, an area of hydrophobicity is created **(B)** close to the polar heads of the cell membrane. It is predicted that substitution of arginine with tryptophan at position 338 changes the hydrophobicity of this area, making it neutral in charge **(C)**. In addition, the bulky side-chain of tryptophan introduces clashes with surrounding side chains of lysine 363 and asparagine 335 **(E)**, disrupting the overall structure of the protein in this region.](fnmol-08-00083-g0002){#F2}

Mutation R338W in Collybistin Disrupts Phosphatidylinositol-3-Phosphate Binding {#s3-3}
-------------------------------------------------------------------------------

The CB PH domain has previously been shown to play a key role in binding PI~3~P/PtdIns-3-P, a phosphoinositide with an emerging role in membrane trafficking and signal transduction. Deletion of the CB PH domain, or mutation of two key arginine residues (R356/R357) involved in PI~3~P binding has been demonstrated to abolish CB-mediated gephyrin clustering in functional assays (Harvey et al., [@B6]; Kalscheuer et al., [@B11]; Reddy-Alla et al., [@B26]). In order to determine whether the R338W mutation affected CB binding to PI~3~P, we performed pulldown assays using PI~3~P immobilized on agarose beads incubated with lysates of HEK293 cells transfected with either wild-type CB variant CB3~SH3−~ or mutant CB3~SH3−~^R338W^. Total expression of CB3~SH3−~^R338W^ was not significantly different to wild-type CB3~SH3−~ when normalized to β-actin expression (Figure [3A](#F3){ref-type="fig"}, left and right panels, wild-type CB2~SH3−~ 1.00 ± 0.23 vs. R338W 1.16 ± 0.33; normalized to wild-type ± SEM, *n* = 5). However, when the PI~3~P pull-down fraction was expressed as a percentage of raw input, a significant reduction of PI~3~P binding was observed for the R338W variant (Figure [3A](#F3){ref-type="fig"}, middle and right panels, wild-type 100 ± 13.5 vs. R338W 38 ± 8.6; pull-down fraction ± SEM, *n* = 5, *p* \< 0.006).

![**R338W reduces collybistin PI~3~P binding and prevents formation of collybistin-mediated submembrane gephyrin clusters in cellular assays. (A)** Human embryonic kidney (HEK293) cells were transfected with plasmids encoding myc-CB3~SH3−~ or myc-CB3~SH3−~^R338W^ and cell lysates incubated with PI~3~P-conjugated agarose beads. After washing, bound material was subjected to SDS-PAGE and analyzed by immunoblotting with an anti-myc antibody (Sigma). Notably, no significant difference was observed in total level of myc-CB3~SH3−~^R338W^ expression in comparison with wild-type CB3~SH3−~, using β-actin as a loading control (**A**, left and right panels, normalized to wild-type 1.00 ± 0.23 vs. R338W 1.16 ± 0.33; wild-type ± SEM, *n* = 5). myc-CB3~SH3−~^R338W^ binding to PI~3~P was significantly reduced (62.7% ± 3.9%) in comparison to wild-type CB3~SH3−~. When we assessed the PI~3~P pull-down fraction as a percentage of the raw input, we saw a significant difference between wild-type and the R338W variant (**A**, middle and right panels; wild-type 100 ± 13.5 vs. R338W 38 ± 8.6; pull-down fraction ± SEM, *n* = 5, \*\**p* \< 0.006, unpaired student's *t*-test). No β-actin immunoreactivity was observed in PI~3~P pull-down samples, confirming the validity of this assay. **(B--G)** HEK293 cells were co-transfected with EGFP-gephyrin alone **(B)**, or with myc-CB3~SH3−~ **(C)**, myc-CB3~SH3+~ **(D)**, myc-CB3~SH3−~^R338W^ **(E)**, or the PI~3~P binding defective mutants myc-CB3~SH3−~^R290H^ **(F)**, and myc-CB3~SH3−~^R356N/R357N^ **(G)**. Cells were immunostained using anti-myc and AlexaFluor 546 antibodies and co-stained with a nuclear marker (DAPI). Note that while myc-CB3~SH3−~ co-localizes with gephyrin in submembrane clusters, all other CB variants co-localize with gephyrin in large intracellular aggregates, consistent with a lack of CB-mediated gephyrin clustering activity. Scale bar = 10 μm. **(C)** is a Z-projection, all other images are single plane.](fnmol-08-00083-g0003){#F3}

Mutation R338W Disrupts Collybistin-Mediated Gephyrin Clustering {#s3-4}
----------------------------------------------------------------

Given the key role of CB in mediating gephyrin clustering at inhibitory synapses, we also investigated whether the R338W substitution affected the ability of CB to translocate gephyrin to submembrane microaggregates in a cellular clustering assay (Harvey et al., [@B6]; Kalscheuer et al., [@B11]). This involved co-expression of myc-tagged human CB (myc-CB3~SH3−~; Kalscheuer et al., [@B11]) with EGFP-gephyrin in HEK293 cells. CB variants containing the regulatory SH3 domain (CB3~SH3+~) typically co-localize with EGFP-gephyrin in large intracellular aggregates (Figures [3B,D](#F3){ref-type="fig"}; Kins et al., [@B12]; Harvey et al., [@B6]; Kalscheuer et al., [@B11]) and require neuroligins, GABA~A~R α2 or the small Rho-like GTPase TC10 for activation (Poulopoulos et al., [@B24]; Saiepour et al., [@B28]; Mayer et al., [@B18]). However, variants lacking the regulatory SH3 domain (e.g., CB3~SH3−~) typically result in the formation of EGFP-gephyrin submembrane clusters (Figure [3C](#F3){ref-type="fig"}). However, the CB3~SH3−~^R338W^ variant did not result in the formation of submembrane microaggregates with EGFP-gephyrin, but rather co-localized with EGFP-gephyrin in large intracellular aggregates (Figure [3E](#F3){ref-type="fig"}) similar to the distribution previously observed for CB3~SH3+~ or CB mutants that disrupt PI~3~P binding, such as R290H and the double mutant R356N/R357N (Figures [3F,G](#F3){ref-type="fig"}; Reddy-Alla et al., [@B26]; Papadopoulos et al., [@B21]). This demonstrates that the R338W substitution disrupts CB-mediated accumulation of gephyrin in submembrane microclusters.

Discussion {#s4}
==========

This study reports the identification and functional characterization of a novel mutation (p.R338W) in *ARHGEF9* that is likely to represent the cause of XLID in family K8010. Using next-generation X-exome sequencing, Affected Kindred/Cross-Cohort Analysis and inheritance testing, we found a novel SNV (c.1012C\>T; p.R338W) in *ARHGEF9* that segregated with the disease phenotype. Using molecular modeling and functional assays for CB PI~3~P binding and gephyrin clustering, we were able to establish the likely pathomechanism for p.R338W: a local disruption in the PH domain structure, leading to a reduction in PI~3~P binding and/or PH domain folding, and consequent loss in the ability of CB to mediate gephyrin clustering in an *in vitro* assay. The identification of *ARHGEF9* as the causative gene for family K8010 is consistent with previous studies that have identified CB as a neuronally-expressed RhoGEF with a key role in inhibitory synaptic transmission (Kins et al., [@B12]; Harvey et al., [@B6]). At selected inhibitory synapses, CB interacts with gephyrin (Kins et al., [@B12]; Harvey et al., [@B6]), a scaffolding protein with dual roles in inhibitory receptor clustering and molybdenum co-factor synthesis (Feng et al., [@B4]). CB knockout mice show increased anxiety and impaired spatial learning associated with a selective loss of GABA~A~Rs in the basolateral amygdala and hippocampus (Papadopoulos et al., [@B20]). Unsurprisingly, loss of CB clearly leads to significant changes in GABAergic inhibition, network excitability and synaptic plasticity (Jedlicka et al., [@B8]). Recent studies have also implicated CB in mTOR signaling: CB physically interacts with mTOR and inhibits mTORC1 signaling pathway and protein synthesis (Machado et al., [@B16]). This suggests that disruption of mTORC1 signaling pathways could also contribute to ID in patients with *ARHGEF9* loss-of-function mutations.

A number of mutations in *ARHGEF9* have been identified in patients encompassing missense and nonsense mutations, deletions and complex rearrangements (Table [1](#T1){ref-type="table"}). Curiously, the associated phenotypes vary quite substantially. For example, Harvey et al. ([@B6]) reported a p.G55A missense mutation in *ARHGEF9* associated with hyperekplexia, early infantile epileptic encephalopathy and severe psychomotor retardation (p.G55A, SH3 domain). By contrast, Shimojima et al. ([@B29]) identified an *ARHGEF9* nonsense mutation (p.Q2X) in an individual with refractory seizures, right frontal polymicrogyria and severe psychomotor retardation. Lemke et al. ([@B13]) also reported a p.R290H missense mutation in the CB RhoGEF domain associated with epilepsy and ID. Furthermore, large *de novo* deletions affecting *ARHGEF9* as well as neighboring genes *SPIN4* and *LOC92249* have been reported to be associated with complex phenotypes that include features such as partial seizures, delayed psychomotor development and generalized overgrowth (Table [1](#T1){ref-type="table"}; Lesca et al., [@B14]; Shimojima et al., [@B29]). Lastly, a balanced chromosomal translocation (Kalscheuer et al., [@B11]) and a paracentric inversion (Marco et al., [@B17]) have been reported with yet more clinical features, including disturbed sleep-wake cycle, increased anxiety and aggressive behavior or hyperarousal, respectively.

###### 

***ARHGEF9* mutations and associated phenotypes**.

  Mutation type                     Nucleotide                                                                   Protein                                                                                                                                                                                                                               Reported phenotype                                                                           Reference
  --------------------------------- ---------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- ---------------------------
  Missense and nonsense mutations   c.4C\>T                                                                      p.Q2X                                                                                                                                                                                                                                 Refractory seizures, right frontal polymicrogyria, severe psychomotor retardation, ataxia    Shimojima et al. ([@B29])
                                    c.869G\>A                                                                    p.G55A                                                                                                                                                                                                                                Hyperekplexia, early infantile epileptic encephalopathy and severe psychomotor retardation   Harvey et al. ([@B6])
                                    c.869G\>A                                                                    p.R290H                                                                                                                                                                                                                               Epilepsy and intellectual disability                                                         Lemke et al. ([@B13])
                                    c.1012C\>T                                                                   p.R338W                                                                                                                                                                                                                               Intellectual disability with variable macrocephaly and macro-orchidism                       This study
  Deletions                         *De novo* 737 kb deletion including *ARHGEF9, SPIN4, LOC92249*               Complex partial seizures, severely delayed psychomotor development, generalized overgrowth and trigonocephaly                                                                                                                         Kalscheuer et al. ([@B11])                                                                   
                                    *De novo* 1.29 Mb deletion of Xq11.11 including *ARHGEF9, SPIN4, LOC92249*   Delayed psychomotor development, loss of consciousness, hypotonia, cyanosis, generalized overgrowth, mild dysmorphic features, hyperactivity with attention deficit, limited social interaction                                       Marco et al. ([@B17])                                                                        
  Complex rearrangements            Balanced translocation 46, X, t(Xq11.1;18q11.21)                             Disturbed sleep-wake cycle, late-onset epileptic seizures, increased anxiety, aggressive behavior and intellectual disability                                                                                                         Kalscheuer et al. ([@B11])                                                                   
                                    Balanced *de novo* paracentric inversion (X)(q11.1;q27.3)                    Hyperarousal (noise and social situations), global developmental delay, dysarthric speech, difficulty with smooth eye pursuit, bilateral lower extremity spasticity, brisk reflexes and extensor plantar responses, wide-based gait   Marco et al. ([@B17])                                                                        

The exact reasons behind this clinical variability remains unknown, but are likely to be linked to several factors. Firstly, certain CB mutations (e.g., p.G55A, p.R290H, C-terminal truncations) clearly cause dominant-negative effects on gephyrin and GABA~A~ receptor clustering in neuronal systems (Harvey et al., [@B6]; Kalscheuer et al., [@B11]; Papadopoulos et al., [@B21]). Secondly, for female patients with CB mutations, the clinical features observed may depend on the degree of X-inactivation skewing. At least two studies involving a translocation or inversion in *ARHGEF9* have indicated skewed X inactivation in favor of the abnormal X chromosome (Marco et al., [@B17]; Kalscheuer et al., [@B11]). However, one emerging theme in functional studies of CB missense mutations appears to be loss of PI~3~P binding. Our own functional analysis suggests that the p.R338W variant causes a local disruption in the PH domain structure, leading to a reduction in PI~3~P binding and/or PH domain folding, and consequent loss in the ability of CB to mediate gephyrin clustering. Similar findings have recently been reported for the p.R290H mutation linked to epilepsy and ID, which appears to alter the strength of intramolecular interactions between the RhoGEF and PH domains, also leading to a loss of PI~3~P binding affinity (Papadopoulos et al., [@B21]). These results highlight the key role of phosphoinositide binding and correct localization of CB for synaptic function. However, given the variability in clinical phenotypes associated with CB mutations, it is also evident that next-generation sequencing diagnostics have a pivotal role to play in the diagnosis of X-linked disorders.
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